Department of Tropical Medicine and Gastroenterology, Qena Faculty of Medicine, South Valley University, Qena, Egypt.
Department of Internal Medicine, Division of Gastroenterology and Hepatology, Qena Faculty of Medicine, South Valley University, Qena, Egypt.
Acta Gastroenterol Belg. 2024 Apr-Jun;87(2):274-281. doi: 10.51821/87.2.12205.
NAFLD is thought to affect approximately one-fourth of the world's population. Therefore, we evaluated the role of serum complement and immunoglobulins in the NAFLD pathogenesis.
200 participants were used in this study, divided into two groups; Group I: 100 NAFLD patients and Group II: 100 healthy volunteers. The diagnosis of NAFLD is based on non-invasive methods, following the EASL guideline 2022. IgG, IgM, IgA, C3, and C4 assays were performed on all participants.
When the immunological profiles of patients with NAFLD and healthy controls were compared, it was found that the mean IgA in NAFLD patients was (4.20±5.07), whereas the mean IgA in healthy controls was (2.22±1.05) (P=0.000). Additionally, a significant increase in IgG was found in NAFLD patients (17.08±3.87) compared with healthy controls (11.59±3.34), with a P value of (p<0.001). complement C3 and complement C4 levels significantly increased in nonalcoholic fatty liver disease patients (1.28± 0.61 and 0.40 ± 0.19, respectively), compared to healthy controls (0.90 ±0.27 and 0.30 ±0.12, respectively), with a significant P value (p<0.001 for each).
Elevated IgA, IgG, C3 and C4 exist in patients with NAFLD and could be associated with fatty liver development and progression of hepatic fibrosis in patients with NAFLD.
非酒精性脂肪性肝病（NAFLD）据估计影响着全球四分之一的人口。因此，我们评估了血清补体和免疫球蛋白在 NAFLD 发病机制中的作用。
本研究纳入 200 名参与者，分为两组；组 I：100 名 NAFLD 患者；组 II：100 名健康志愿者。NAFLD 的诊断基于非侵入性方法，并遵循 2022 年 EASL 指南。对所有参与者进行 IgG、IgM、IgA、C3 和 C4 检测。
比较 NAFLD 患者和健康对照组的免疫学特征时，发现 NAFLD 患者的平均 IgA 为（4.20±5.07），而健康对照组的平均 IgA 为（2.22±1.05）（P=0.000）。此外，NAFLD 患者的 IgG 显著升高（17.08±3.87），而健康对照组为（11.59±3.34），P 值（p<0.001）。与健康对照组相比（分别为 0.90±0.27 和 0.30±0.12），非酒精性脂肪性肝病患者的补体 C3 和补体 C4 水平显著升高（分别为 1.28±0.61 和 0.40±0.19），具有显著的 P 值（p<0.001）。
NAFLD 患者存在升高的 IgA、IgG、C3 和 C4，可能与脂肪肝的发生以及 NAFLD 患者肝纤维化的进展有关。
